SEC Comment Letter for Outlook Therapeutics, (OTLK) — Feb 27, 2019
Outlook Therapeutics, Inc.
Date: Feb. 27, 2019 · CIK: 0001649989 · Accession: 0000000000-19-003313
AI Filing Summary & Sentiment
File numbers found in text: 333-229761
Letter
February 27, 2019 Lawrence A. Kenyon President, Chief Executive Officer and Chief Financial Officer Outlook Therapeutics, Inc. 7 Clarke Drive Cranbury, NJ 08512 Re:Outlook Therapeutics, Inc. Registration Statement on Form S-1 Filed February 21, 2019 File No. 333-229761 Dear Mr. Kenyon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Pia Kaur, Esq.
Show Raw Text
February 27, 2019
Lawrence A. Kenyon
President, Chief Executive Officer and Chief Financial Officer
Outlook Therapeutics, Inc.
7 Clarke Drive
Cranbury, NJ 08512
Re:Outlook Therapeutics, Inc.
Registration Statement on Form S-1
Filed February 21, 2019
File No. 333-229761
Dear Mr. Kenyon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Pia Kaur, Esq.